The proposed bill mandates that, starting January 1, 2026, all individual and group health insurance contracts that provide prescription coverage in Rhode Island must include coverage for at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution. The bill specifies that there will be no copayment or deductible required for obtaining two glucagon auto-injectors or equivalent formulations every twelve months. However, it allows for a deductible to be applied to health plans paired with federally qualified health savings accounts, and it does not prevent health plans from implementing this benefit before the specified date.

The bill amends several chapters of the General Laws, including those related to accident and sickness insurance policies, nonprofit hospital service corporations, nonprofit medical service corporations, and health maintenance organizations, by adding a new section that outlines these requirements. The intent of the legislation is to improve access to life-saving glucagon medications for individuals experiencing hypoglycemia, particularly in emergency situations where timely administration is critical.